The lab announced expansion of its early-phase clinical research capabilities, allowing faster translation of discoveries into human studies. The new infrastructure supports first-in-human trials and complex investigational therapies.

The expansion mirrors global investment trends in specialized clinical trial centers designed to bring experimental treatments closer to patient populations and accelerate therapy access.

The new facility will support oncology, metabolic disease, and immunotherapy trials, reinforcing the lab’s role in advancing next-generation therapies through early-stage research.